UR-3216: a new generation oral platelet GPIIb/IIIa antagonist.

Abstract

Various oral platelet GPIIb/IIIa receptor antagonists have undergone clinical investigations, but to date without success. Various factors have been proposed to explain their failure such as low affinity for the receptor, large peak/trough ratio, low bioavailability, partial agonist activity and pro-aggregatory effect. Efforts to discover a truly effective… (More)

Topics

  • Presentations referencing similar topics